✦ LIBER ✦

Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus ≥65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study)

✍ Scribed by Matti J. Tikkanen; Ingar Holme; Nilo B. Cater; Michael Szarek; Ole Faergeman; John J.P. Kastelein; Anders G. Olsson; Mogens Lytken Larsen; Christina Lindahl; Terje R. Pedersen

Book ID: 113445338
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 205 KB
Volume: 103
Category: Article
ISSN: 0002-9149
DOI: 10.1016/j.amjcard.2008.10.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of Atorvastatin 80 mg/day Ver

Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)

✍ Terje R. Pedersen; Nilo B. Cater; Ole Faergeman; John J.P. Kastelein; Anders G. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 592 KB

Safety and Efficacy of Ezetimibe Added t

Safety and Efficacy of Ezetimibe Added to Atorvastatin Versus Up Titration of Atorvastatin to 40 mg in Patients ≥65 Years of Age (from the ZETia in the ELDerly [ZETELD] Study)

✍ Franklin Zieve; Nanette K. Wenger; Ori Ben-Yehuda; Christian Constance; Steven B 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 992 KB

Economic evaluation of high-dose (80&#xa

Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial

✍ Monika Wagner; Peter Lindgren; Elizabeth Merikle; Mireille Goetghebeur; Bengt Jö 📂 Article 📅 2009 🏛 Pulsus Group Inc 🌐 English ⚖ 856 KB